Manufacturer of Controlled Substances Registration: Siemens Healthcare Diagnostics, Inc., 34693 [2015-14912]
Download as PDF
<![CDATA[
34693
Federal Register / Vol. 80, No. 116 / Wednesday, June 17, 2015 / Notices
management strategies for Fire Island
National Seashore for the next 15 to 20
years to support the protection of
important natural resources and
processes; significant recreation
resources; cultural resources of national,
state, and local significance; and
residential communities.
The park is composed of two distinct
units—the barrier island that runs
parallel to the south shore of Long
Island and the 613-acre William Floyd
Estate situated on the south shore of
Long Island near the east end of Fire
Island. To address the specific needs of
these two distinct units, the Draft GMP/
EIS includes two sets of alternatives.
One addresses park-wide alternatives
for Fire Island National Seashore with a
primary emphasis on the barrier island
and includes a no-action alternative and
two action alternatives. The other set of
alternatives focuses specifically on the
William Floyd Estate and includes a noaction and a single action alternative.
The Draft GMP/EIS also incorporates
plans for the Otis Pike High Dunes Fire
Island Wilderness and includes a draft
Wilderness Stewardship Plan for public
review concurrent with the Draft GMP/
EIS.
FOR FURTHER INFORMATION CONTACT:
Ellen Carlson, NPS/Northeast Region, 15
State Street, Boston, MA 02019. Phone:
(617) 223–5048. Email: Fire_Island_
GMP@nps.gov.
Dated: June 1, 2015.
Michael A. Caldwell,
Regional Director, Northeast Region, National
Park Service.
[FR Doc. 2015–14927 Filed 6–16–15; 8:45 am]
BILLING CODE 4310–WV–P
continuation or recurrence of material
injury to an industry in the United
States within a reasonably foreseeable
time.
Background
The Commission, pursuant to section
751(c) of the Tariff Act of 1930 (19
U.S.C. 1675(c)), instituted these reviews
on April 1, 2014 (79 FR 18311) and
determined on July 7, 2014 that it would
conduct full reviews (79 FR 42049, July
18, 2014). Notice of the scheduling of
the Commission’s reviews and of a
public hearing to be held in connection
therewith was given by posting copies
of the notice in the Office of the
Secretary, U.S. International Trade
Commission, Washington, DC, and by
publishing the notice in the Federal
Register on November 14, 2014 (79 FR
68299). The hearing was held in
Washington, DC, on March 26, 2015,
and all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission made these
determinations pursuant to section
751(c) of the Tariff Act of 1930 (19
U.S.C. 1675(c)). It completed and filed
its determinations in these reviews on
June 11, 2015. The views of the
Commission are contained in USITC
Publication 4538 (June 2015), entitled
Citric Acid and Certain Citrate Salts
from Canada and China: Investigation
Nos. 701–TA–456 and 731–TA–1151–
1152 (Review).
By order of the Commission.
Issued: June 12, 2015.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2015–14863 Filed 6–16–15; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
DEPARTMENT OF JUSTICE
[Investigation Nos. 701–TA–456 and 731–
TA–1151–1152 (Review)]
Drug Enforcement Administration
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Citric Acid and Certain Citrate Salts
From Canada and China
[Docket No. DEA–392]
Determination
On the basis of the record 1 developed
in the subject five-year reviews, the
United States International Trade
Commission (‘‘Commission’’)
determines, pursuant to the Tariff Act of
1930, that revocation of the
countervailing duty order on citric acid
and certain citrate salts from China and
the antidumping duty orders on citric
acid and certain citrate salts from China
and Canada would be likely to lead to
1 The
record is defined in sec. 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
VerDate Sep<11>2014
18:47 Jun 16, 2015
Jkt 235001
Manufacturer of Controlled
Substances Registration: Siemens
Healthcare Diagnostics, Inc.
ACTION:
Notice of registration.
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
Controlled substance
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Schedule
I
II
II
II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator controls which are
DEA exempt products.
In reference to drug code 7370 the
company plans to bulk manufacture a
synthetic tetrahydrocannabinol. No
other activity for this drug code is
authorized for this registration.
Dated: June 11, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–14912 Filed 6–16–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Siemens Healthcare
Diagnostics, Inc. applied to be registered
as a manufacturer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
(DEA) grants Siemens Healthcare
Diagnostics, Inc. registration as a
manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice
dated January 9, 2015, and published in
SUMMARY:
the Federal Register on January 26,
2015, 80 FR 3982, Siemens Healthcare
Diagnostics, Inc., Attn: RA, 100 GBC
Drive, Mailstop 514, Newark, Delaware
19702 applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted to this notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of Siemens Healthcare
Diagnostics, Inc. to manufacture the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Drug Enforcement Administration
[Docket No. DEA–411F]
Adjusted Aggregate Production
Quotas for Difenoxin, Diphenoxylate
(for Conversion), and Marijuana
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
E:\FR\FM\17JNN1.SGM
17JNN1
]]>Agencies
[Federal Register Volume 80, Number 116 (Wednesday, June 17, 2015)]
[Notices]
[Page 34693]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-14912]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Siemens
Healthcare Diagnostics, Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Siemens Healthcare Diagnostics, Inc. applied to be registered
as a manufacturer of certain basic classes of controlled substances.
The Drug Enforcement Administration (DEA) grants Siemens Healthcare
Diagnostics, Inc. registration as a manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice dated January 9, 2015, and
published in the Federal Register on January 26, 2015, 80 FR 3982,
Siemens Healthcare Diagnostics, Inc., Attn: RA, 100 GBC Drive, Mailstop
514, Newark, Delaware 19702 applied to be registered as a manufacturer
of certain basic classes of controlled substances. No comments or
objections were submitted to this notice.
The DEA has considered the factors in 21 U.S.C. 823(a) and
determined that the registration of Siemens Healthcare Diagnostics,
Inc. to manufacture the basic classes of controlled substances is
consistent with the public interest and with United States obligations
under international treaties, conventions, or protocols in effect on
May 1, 1971. The DEA investigated the company's maintenance of
effective controls against diversion by inspecting and testing the
company's physical security systems, verifying the company's compliance
with state and local laws, and reviewing the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Ecgonine (9180)............................ II
Morphine (9300)............................ II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The company plans to produce the listed controlled substances in
bulk to be used in the manufacture of reagents and drug calibrator
controls which are DEA exempt products.
In reference to drug code 7370 the company plans to bulk
manufacture a synthetic tetrahydrocannabinol. No other activity for
this drug code is authorized for this registration.
Dated: June 11, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-14912 Filed 6-16-15; 8:45 am]
BILLING CODE 4410-09-P
